Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiprotozoal agents: How have they changed over a decade?

Antiprotozoal agents: How have they changed over a decade? Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low‐ or low‐to‐middle‐income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archiv Der Pharmazie Wiley

Loading next page...
 
/lp/wiley/antiprotozoal-agents-how-have-they-changed-over-a-decade-JGRe8kvHqP

References (249)

Publisher
Wiley
Copyright
© 2022 Deutsche Pharmazeutische Gesellschaft
ISSN
0365-6233
eISSN
1521-4184
DOI
10.1002/ardp.202100338
Publisher site
See Article on Publisher Site

Abstract

Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low‐ or low‐to‐middle‐income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.

Journal

Archiv Der PharmazieWiley

Published: Feb 1, 2022

Keywords: Chagas disease; leishmaniasis; malaria; medicinal chemistry; neglected diseases; parasitic diseases; sleeping sickness

There are no references for this article.